RecruitingNot ApplicableNCT07140744

A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint

A Prospective Diagnostic Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint in Primary and Secondary/Tertiary Care

Sponsor

Eli Lilly and Company

Enrollment

7,000 participants

Start Date

Aug 22, 2025

Study Type

INTERVENTIONAL

Conditions

Subjective Cognitive Impairment

Summary

The purpose of the study is to measure the difference in the proportion of participants with prespecified patient management actions between a tested interventional group and a control group.

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying P-tau217 and Standard of Care for people with subjective cognitive impairment. The study is currently recruiting participants at 1 location. People eligible for this study include aged 50 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTP-tau217

Blood biomarker testing

OTHERStandard of Care

Standard of care

Locations(1)

SiteRx Virtual Site

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07140744

Related Trials

Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment

NCT061503521 location

Sleep Apnea and Cognitive Function in Subjects With Subjective or Mild Cognitive Impairment

NCT060890961 location